ArticleNanomedicine (London, England)2013
Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer.
Article in Nanomedicine (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer.Nanomedicine (London, England) · 2026Article
- Next-generation nanocarriers for precision antitumor therapy: from passive targeting to intelligent response.Exploration of targeted anti-tumor therapy · 2025Review
- Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024.Pharmaceutics · 2024Review
- Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems.Pharmaceutics · 2023Review
- Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges.Journal of nanobiotechnology · 2022Review
- Molecular Markers in Urinary Bladder Cancer: Applications for Diagnosis, Prognosis and Therapy.Veterinary sciences · 2022Review
- Application of nanotechnology in the diagnosis and treatment of bladder cancer.Journal of nanobiotechnology · 2021Review
- Combination strategies to maximize the benefits of cancer immunotherapy.Journal of hematology & oncology · 2021Review
- Preclinical Models for Bladder Cancer Research.Hematology/oncology clinics of North America · 2021Review
- Review
- Telodendrimers: Promising Architectural Polymers for Drug Delivery.Molecules (Basel, Switzerland) · 2020Review
- Relationship between the genetic expression of WTAP and bladder cancer and patient prognosis.Oncology letters · 2018Article
- Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo.Nanomedicine (London, England) · 2018Article
- Increased endocytosis of magnetic nanoparticles into cancerous urothelial cells versus normal urothelial cells.Histochemistry and cell biology · 2018Article
- Targeting and Internalization of Liposomes by Bladder Tumor Cells Using a Fibronectin Attachment Protein-Derived Peptide-Lipopolymer Conjugate.Bioconjugate chemistry · 2017Article
- Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.Nanomedicine (London, England) · 2017Article
- Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer.Nanotechnology · 2016Article
- Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.Biomaterials · 2016Article
- Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery.Pharmaceutical patent analyst · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
aimThis work aimed to determine if the treatment outcomes of bladder cancer could be improved by targeting micelles that are decorated with bladder cancer-specific ligands on the surface and loaded with the chemotherapeutic drug paclitaxel. MATERIALS &
methodsTargeting efficacy and specificity was determined with cell lines. An in vivo targeting and anti-tumor efficacy study was conducted in mice carrying patient-derived xenografts. RESULTS & DISCUSSION: Targeting micelles were more efficient than nontargeting micelles in delivering the drug load into bladder cancer cells both in vitro and in vivo (p < 0.05). The micelle formulation of paclitaxel was less toxic than free paclitaxel in Cremophor(®) (Sigma, MO, USA) and allowed administration of three-times the maximum tolerated dose without increasing the toxicity. Targeting micelles were more effective than the nontargeting micelles in controlling cancer growth (p = 0.0002) and prolonging overall survival (p = 0.002).
conclusionTargeting micelles loaded with paclitaxel offer strong potential for clinical applications in treating bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.